Effects of Ginkgo biloba Extract on Inflammatory Mediators (SOD, MDA, TNF-α, NF-κBp65, IL-6) in TNBS-Induced
Colitis in Rats by Zhou, Yan-Hong et al.
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2006, Article ID 92642, Pages 1–9
DOI 10.1155/MI/2006/92642
ResearchCommunication
Effects of Ginkgobiloba Extract on Inﬂammatory Mediators
(SOD, MDA, TNF-α,N F - κBp65, IL-6) in TNBS-Induced
Colitis in Rats
Yan-Hong Zhou,1 Jie-Ping Yu,1 Yi-Fei Liu,2 Xiao-Jun Teng,1 Mei Ming,1 Peng Lv,1 Ping An,1
Shi-Quan Liu,1 and Hong-Gang Yu1
1Department of Gastroenterology, Renmin Hospital, Wuhan University, Hubei Province, Wuhan 430060, China
2Department of Biomedical Engineering, Xianning University, Hubei Province, Xianning 437100, China
Received 21 April 2006; Revised 30 July 2006; Accepted 7 August 2006
Inﬂammatory mediators play a criticial role in ulcerative colitis immune and inﬂammatory processes. The aim of the study was to
investigatetheeﬀectsofGinkgobilobaextractoninﬂammatorymediators(SOD,MDA,TNF-α,NF -κBp65,IL-6)inTNBS-induced
colitis in rats. Colitis in rats was induced by colonic administration with 2,4,6-trinitrobenzene sulfonic acid (TNBS, 150mg/kg).
EGB in doses of (50, 100, 200mg/kg) was administered for 4 weeks to protect colitis. The results showed that EGB could sig-
niﬁcantly ameliorate macroscopic and histological damage, evidently elevate the activities of SOD and reduce the contents of
MDA, inhibit the protein and mRNA expressions of TNF-α,N F - κBp65, and IL-6 in the colon tissues of experimental colitis in
a dose-dependent manner compared with the model group. We concluded that the probable mechanisms of EGB ameliorated
inﬂammatory injury in TNBS-induced colitis in rats by its modulation of inﬂammatory mediators and antioxidation
Copyright © 2006 Yan-Hong Zhou et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two
major categories of inﬂammatory bowel disease (IBD). Al-
though the etiology and pathophysiology still remains un-
clear, immune dysfunction plays a crucial role in the de-
velopment of UC [1]. Inﬂammatory mediators, including
reactive oxygen species (ROS) and cytokines, contribute to
the inﬂammatory cascade in modulating the immune sys-
tem of IBD [2–4]. Proinﬂammatory cytokines such as tumor
necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and
interleukin-6(IL-6) in the colonic mucosa signiﬁcantly in-
creased and antiinﬂammatory cytokines such as interleukin-
4(IL-4) and interleukin-10(IL-10) signiﬁcantly decreased in
UC [5]. Of the various kinds of inﬂammatory mediators,
TNF-α, which is induced, synthesized and secreted from
macrophages, lymphocytes, and polymorphonuclear neu-
trophils, is regarded as the most prominent “ﬁrst-line” cy-
tokines [6, 7]. TNF-α stimulate and induce the production
of other inﬂammatory mediators such as ROS, and it also
activate oxidative stress-responsive genes which amplify and
prolonginﬂammation[8].Moreover,TNF-αhasoverlapping
and synergetic activities to induce the production of nuclear
factor-κB( N F - κB) and other cytokines [9].
Growing evidence demonstrated the signiﬁcance of ox-
idative stress both in the clinical and experimental studies
of UC. The increase of ROS and the impairment of antiox-
idant defense mechanisms were postulated to be causative
factors in inﬂammatory diseases [10]. Excessive production
of ROS in mucosal cells induced inﬂammatory and im-
mune responses which could directly or indirectly cause
damage of intestinal epithelial cells, subsequently inﬂuence
mucosal integrity or initiate an inﬂammatory signaling cas-
cade and lead to severe impairment in experimental colitis
[11, 12]
Furthermore, oxidative stress and TNF-α could activate
and induce NF-κB. NF-κB existed in the cytoplasm in an in-
active form by virtue of its association with IκBs. Once ac-
tivated, NF-κB translocated to the nucleus from the cyto-
plasm, then activated the consensus sequence related gene,
including TNF-α, IL-6, IL-2, IL-8, ICAM-1, and so forth,
involved in immune and inﬂammatory responses [13, 14].
On the other hand, elevated TNF-α might be a positive-
feedbacksignalthattriggeredNF-κBreactivation.Eventually,2 Mediators of Inﬂammation
the inﬂammatory reaction of the UC was ampliﬁed and per-
petuated by the pathogenic cascade.
Therapy of UC is diﬃcult on account of the complex eti-
ology of disease. As a naturally remitting and recurring dis-
ease, the patients with IBD run a higher risk to develop col-
orectal cancer than the average population. Although thera-
peutic drugs such as 5-aminosalicylic acid (5-ASA), sulfasul-
fapyridine (SASP), and glucocorticoids could inhibit the in-
ﬂammatory mediators through diﬀerent mechanisms which
engaged in the down-regulation of the immune and inﬂam-
matory responses of IBD [15, 16], their adverse reactions
during prolonged treatment and high relapse rate limited
their use. It is important that eﬀective drugs with fewer ad-
verse reactions should be developed to prevent UC from ini-
tiating and relapsing.
Ginkgo biloba extract (EGB), a natural antioxidant, is an
extract from green leaves of the Ginkgo biloba tree. The main
ingredients of EGB contain 24% ginkgo-ﬂavone glycosides
and 6% terpenoids. It is well known for its cheap prices and
negligible side eﬀects. EGB has various biological activities
and diﬀerent pharmacologic eﬀects, including antioxidation,
antiinﬂammatory and modulation of immune response. For
its few side eﬀects, EGB is extensively used in the therapy of
central neural system disorders, acute pancreatitis, myocar-
dial, and intestine ischemia/reperfusion injury which are as-
sociated with inﬂammatory mediators [17–20].
The mechanism that EGB aﬀords protection against ul-
cerative colitis remains obscure. This study was designed to
determine the probable mechanisms of EGB in ameliorat-
ing inﬂammatory injury in TNBS-induced colitis in rats, and
to investigate its eﬀects on the production of inﬂammatory
mediators involved in the immune and inﬂammatory re-
sponses, including Superoxide dismutase (SOD), malondi-
aldehyde (MDA), TNF-α,N F - κBp65 and IL-6. The eﬀects of
EGB on colonic inﬂammation and macroscopic and histo-
logical damage were evaluated as well.
MATERIALS AND METHODS
Animals
Purebred male Wistar rats (180
￿20g) were purchased from
the Experimental Animal Center of Hubei Province (Wuhan,
C h i n a ) .T h er a t sw e r ea l l o w e dt oa d a p tt oo u rl a b o r a t o r ye n -
vironment for one week before beginning the experiment.
They were housed in standard cages with free access to tap
water and maintained in a room under standard condi-
tions of feeding and temperature with a 12h : 12h light-
dark cycle. This animal study was approved by the Ethical
and Research Committee of the Wuhan University Medical
School.
Experimentaldesign
These rats were randomly divided into six groups of 12
each, normal group (N group), model group (M group), 5-
aminosalicylic acid(5-ASA group), low-dose EGB group (LD
group), middle-dose EGB group (MD group) and high-dose
EGB group (HD group). Rat model of colitis was induced
with 2,4,6-trinitrobenzene sulfonic acid (TNBS, Sigma Co,
China) enema by using a technique modiﬁed from that of
M o r r i se ta l[ 21]. Brieﬂy, rats were fasted for 24 hours with
access to water ad libitum and observed to ensure health be-
fore induction of colitis. The rats were lightly anesthetized
with ether. A ﬂexible plastic rubber catheter with an outside
diameter of 2mm was inserted 8cm into the colon via the
anus. TNBS (150mg/kg) dissolved in 50% (vol/vol) ethanol
(to break the intestinal barrier) was injected into the colon.
Injection with 50% ethanol instead of TNBS served as a neg-
ative control in N group. All other rats received TNBS en-
ema on day 0. EGB was mixed with saline to a 0.01g/mL
suspension. The drug-treated groups received 5-ASA (Guoyi
Pharmaceutical Ltd, China) in a dose of 100mg/kg and
EGB (Guizhou Xinbang Pharmaceutical Company, China)
in doses of 50, 100 and 200mg/kg by stomach, respectively
(once a day, from the 24 hours after colitis was established
to the end of experiment). In the normal and model groups
of rats, saline was given instead of 5-ASA and EGB, respec-
tively. At the end of a four-week period, ratswere killed using
ether anesthesia and colonic biopsies were taken for macro-
scopic scoring, histopathological examination and biochem-
ical studies.
Assessmentofcolonmacroscopicand
histologicaldamage
Two pathologists who were unaware of the treatment condi-
tionsrecordedthemacroscopicandhistologicaldamage.The
tissue of colon 8cm proximal to anus was excised, opened
longitudinally,andwashedinsalinebuﬀer.Thecriteriaofthe
macroscopicscoreusedapreviouslyvalidatedscoringsystem
from 0 to 4 that depends on the number and size of ulcers as
well as the presence or absence of adhesions [21, 22].
Colon tissue was ﬁxed in 4% paraformaldehyde, dehy-
drated, and paraﬃn embedded, processed, and sectioned
in 4μm thick sections, and stained with haematoxylin and
eosin. The assessment criteria of the histological score was
according to previous literature [21, 22]: (1) the inﬁltration
of acute inﬂammatory cells: 0 = no, 1 = mild increas-
ing, 2 = severe increasing; (2) the inﬁltration of chronic
inﬂammatory cells: 0 = no, 1 = mild increasing, 2 = se-
vere increasing; (3) the deposition of ﬁbrotin protein: 0 =
negative, 1 = positive; (4) the submucosa edema: 0 = no,
1 = patchy-like, 2 = fusion-like; (5) the epithelium necro-
sis: 0 = no, 1 = limiting, 2 = widening; (6) the epithelium
ulcer: 0 = negative, 1 = positive. The ulceration, inﬂam-
mation, lesion and ﬁbrosis were scored and put together as
a result ranging between the minimum of 0 and maximum
of 10.
DeterminationofcolonicSODandMDAlevels
The colon tissue was rinsed and weighed, then put into tubes
with 9 volumes of 9g/L normal saline. Then the tissue sam-
ples were homogenized for 10 minutes. After centrifugation
at 4000r/min for 10 minutes at 4
ÆC, the MDA contentsYan-Hong Zhou et al 3
and SOD activities in the supernatant were measured by the
assay kit (Nanjing Jincheng Corp, China) according to its
provider’s instructions.
Immunohistochemistry
Sections of colon tissues were deparaﬃnized in xylene and
hydrated in a series of graded alcohol. After dewaxing and
rehydration, the antigen retrieval was done by microwave
for 15 minutes. Sections were immersed in 3% hydrogen
peroxide in methanol for 20 minutes at room temperature
to abolish endogeneous peroxidase activities and then they
were blocked with normal goat serum at 37
ÆC for 15 min-
utes.Slideswereincubatedwithpolyclonalantibody ofTNF-
α (diluted to 1 : 100, Santa Cruz Biotechnology) at 37
ÆC
for 60 minutes. After PBS washing, the slides were incu-
bated with a biotinylated horse peroxidase-conjugated sec-
ondaryantibodyand0.1%DABsubstrate,usingthestandard
streptavidin-biotin-based method. Incubation with PBS in-
stead of the primary antibody served as a negative con-
trol. The positive cells were observed and evaluated by two
independent observers. A cytoplasmic brown granule was
marked as a positive expression of TNF-α. The results were
evaluated semiquantitatively according to the percentage of
positive cells in ten randomly selected ﬁelds under high-
power microscope (400-fold magniﬁcation) for each sample.
Westernblotting
Nuclear protein was extracted as described by Huang et
al [23] with some modiﬁcation. Brieﬂy, fresh colon tis-
sue was pounded to pieces in liquid nitrogen, then minced
and homogenized in 400μL of hypotonic lysis buﬀer
(10mmol/L HEPES pH 7.9, 10mmol/L KCl, 0.1mmol/L
EDTA, 0.1mmol/L EGTA, 1mmol/L DTT, 1mmol/L PMSF,
1μg/mL aprotinin, 1μg/mL pepstatin and 1μg/mL leu-
peptin). The samples were separated by centrifugation (0
ÆC,
2000r/min, 15 seconds) and the supernatant was incubated
in ice water for 5 minutes, and then spun by centrifugation
(0
ÆC, 5000r/min, 10 seconds) again. The cytoplasmic pro-
teins were removed and the pellet nuclei were resuspended
in 100μLb u ﬀer (20mmol/L HEPES pH 7.9, 420mmol/L
NaCl, 1mmol/L EDTA, 1mmol/L EGTA, 1mmol/L DTT,
1mmol/L PMSF, 1μg/mL aprotinin, 1μg/mL pepstatin and
1μg/mL leupeptin). The deposits were incubated in ice wa-
ter for 20 minutes. Finally, the samples were separated by
centrifugation (0
ÆC, 12 000r/min, 15 minutes), the super-
natants were collected as nuclear extracts in aliquots and
stored at
￿80
ÆC for western blotting of NF-κBp65. Protein
concentrations were determined by Bradford assay.
Tissue lysates were prepared by sonicating tissues
in lysis buﬀer (50mmol/L Tris-HCl buﬀer, pH 8.0,
150mmol/LNaCl, 1mmol/L EDTA, 1%NP-40, 1%SDS,
0.02% Sodium Azide containing 1g/mL aprotinin, 1g/mL
leupeptin, and 0.2mmol/L PMSF) and centrifuged at
12000r/min for 10 minutes at 4
ÆC, the supernatants were
collected and stored at
￿80
ÆC for Western blotting of TNF-
α and IL-6. Protein concentrations were determined by
Bradford assay. Samples containing equal amounts of pro-
tein (40μg/lane) were separated on a denaturing 12% poly-
acrylamidegelandtransferredtoanitrocellulosemembrane.
Membranes were blocked in 5% Blotto in TBS +0.1% Tween
20, and incubated with anti-TNF-α, anti-NF-κBp65, anti-
IL-6, and anti-β-actin rabbit polyclonal antibodies (diluted
to 1 : 500, 1 : 500, 1 : 500, and 1 : 1000, resp, Santa
Cruz Biotechnology). The membranes were then treated
with horseradish peroxidase-conjugated secondary antibod-
ies (diluted to 1 : 2000, Santa Cruz Biotechnology). Detec-
tionofantibodybindingwasdoneusingtheWesternblotting
Luminol Reagent kit (Santa Cruz Biotechnology) using the
appropriate secondary antibody supplied with the kit. The
membranes were exposed to Kodak X-ray ﬁlm and devel-
oped accordingly. The bands were quantiﬁed by the average
ratios of integral optic density (IOD) of TNF-α/β-actin, NF-
κBp65/-β-actin and IL-6/β-actin, respectively.
Reversetranscriptase-polymerasechain
reaction(RT-PCR)
Total RNA was extracted from a fresh colon sample with
Trizol reagent (Invitrogen Life Technologies Co Ltd, USA.)
following the manufacturer’s protocol. An aliquot of total
RNAwasreversetranscribedandampliﬁedusingMMLVand
TaqDNApolymerase(Promega,Southampton,UK),respec-
tively. The conditions of the PCR ampliﬁcation were 3 min-
utes at 94
ÆC for one cycle, 30 seconds at 94
ÆC, 30 seconds
at 50
ÆC and 45 seconds at 72
ÆCf o r3 5c y c l e s ,7m i n u t e sa t
72
ÆC for one cycle. The sequences of primers of NF-κBp65
(493bp)were:sense,5
 -AAGATCAATGGCTACACGGG-3
 ,
antisense, 5
 -CCTCAATGTCTTCTTTCTGC-3
 ; the primer
for TNF-α (357bp) sense, 5
 -GCCAATGGCATGGATCTC-
AAAG-3
 , antisense, 5
 -CAGAGCAATGACTCCAAAGT-3
 ;
the primer for IL-6(557bp) sense, 5
 -TCTCTCCGCAAGA-
GACTTCC-3
 , antisense, 5
 -TCTTGGTCCTTAGCCACTC-
C-3
 ; the primer for GAPDH (308bp) sense, 5
 -TCCCTC-
AAGATTGTCAGCAA-3
 , antisense, 5
 -AGATCCACAAC-
GGATACATT-3
 . Each PCR products were electrophoresed
in 2% agarose gel and stained with ethidium bromide. The
intensities of the speciﬁc bands were analyzed to determine
whether the diﬀerences were statistically signiﬁcant.
Statisticalanalysis
The results were presented as mean
￿ standard deviation.
Statistical analysis was performed with SPSS 11.5 statistical
software. One way analysis of variance and Student Newman
Keuls Test were used for data analysis. Diﬀerences were con-
sidered signiﬁcant if P<. 05.
RESULTS
Macroscopicpresentationandhistologicalevaluation
As shown in Table 1, macroscopic presentation of the colon
after TNBS treatment revealed colonic mucosal hyperaemia,
oedema, erosion, and some small punctate ulceration.4 Mediators of Inﬂammation
Table 1: Eﬀects of EGB on the macroscopic and histological damage scores and the levels of SOD and MDA of colon tissues in rats. The
results were expressed as means
￿ SD (n = 12).
Group Macroscopic score Histological score SOD (U/mg) MDA (nmol/mg)
N 0.00
￿0.00 0.33
￿0.49 41.51
￿8.28 2.51
￿0.44
M 3.67
￿0.49## 7.17
￿1.26## 22.04
￿3.26## 6.62
￿0.80##
5-ASA 2.33
￿0.49
￿
￿## 4.50
￿1.00
￿
￿ 27.10
￿2.87
￿
￿## 4.77
￿0.60
￿
￿##
LD 3.33
￿0.49## 6.42
￿1.4## 26.63
￿3.68
￿## 5.87
￿0.96
￿##
MD 1.67
￿0.65
￿
￿## 3.75
￿0.87
￿
￿## 31.58
￿2.98
￿
￿## 4.49
￿0.79
￿
￿##
HD 1.25
￿0.45
￿
￿## 2.25
￿0.87
￿
￿## 39.33
￿3.67
￿
￿ 3.70
￿0.79
￿
￿##
￿ denotes that P<. 05 versus the model group.
￿
￿ denotes that P<. 01 versus the model group.
# denotes that P<. 05 versus the normal group.
## denotes that P<. 01 versus the normal group.
(a) (b) (c)
Figure 1:Thehaematoxylinandeosinstainingofcolontissues:(a)nodamageinNgroup(H&E,
￿100);(b)thechangesofhistologywithM
group, the colonic mucosa showed necrotic destruction of epithelium, hemorrhage, edema, inﬂammatory cellular inﬁltration and ulceration
at mucous and submucous layers (H&E,
￿100); (c) the changes of histology with HD EGB (200mg/kg) group (H&E,
￿100).
Conglutination was obvious later. No changes could be
observed in N group. Treatment with 5-ASA reduced the
intensity of the macroscopic score. Treatment with Ginkgo
biloba extract signiﬁcantly reduced the severity of gross le-
sion score in a dose dependent manner. On the other hand,
EGBinthesmalldoseusedhadnosigniﬁcanteﬀectwhilethe
higher doses used had a signiﬁcant eﬀect on the intensity of
inﬂammatory response.
No histological damage was seen in N group. Rats with
TNBS-induced colitis showed a number of neutrophils,
macrophages, lymphocytes and eosinophil inﬁltration in
mucosa and submucosa. Ulceration and mucosal dam-
age were obviously seen. Fibroblasts and granuloma-like
structureswerealsoseen.Treatmentwith5-ASAsigniﬁcantly
attenuated the extent and severity of the histological signs.
Administration with EGB at diﬀerent dosage (50, 100, and
200mg/kg) could inhibit the extents of inﬂammation, pre-
vent the mucosa injury, minimize the ulceration area, and
alleviate the colitis compared with that in model control ani-
mals.TheinhibitioneﬀectwasmostobviouswithEGBatthe
dose of 200mg/kg (Table 1, Figure 1).
DeterminationofcolonicSOD,MDA
Compared with the N group, the activities of SOD notably
decreased and the contents of MDA signiﬁcantly increased in
the M group (P<. 01). Administration with 5-ASA and EGB
(LD, MD, and HD) could elevate the activities of SOD and
reduce the contents of MDA in a dose-dependent manner.
The change was most signiﬁcant in the HD group (P<. 05
or P<. 01, Table 1).
Immunohistochemistry
T h ee x p r e s s i o n so fT N F - α in the M group signiﬁcantly in-
creased compared with the N group. The positive cells of
TNF-α predominantly located within the mucosa and mu-
cosa lamina propria with brown-yellow cytoplasm. Admin-
istration of 5-ASA resulted in a signiﬁcant reduction of
colon TNF-α levels. Compared with the M group, expres-
sions of TNF-α in EGB group weakened signiﬁcantly in a
dose-dependent manner, and the expression in HD group
was the lowest (P<. 01, Figures 2 and 3).Yan-Hong Zhou et al 5
(a) (b) (c)
Figure 2: Immunohistochemical staining for TNF-α: (a) expression of TNF-α in the N group (brown staining, SP
￿400), (b) expression of
TNF-α in the M group (brown staining, SP
￿400), (c) expression of TNF-α in the HD EGB group (brown staining, SP
￿400).
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Figure 3: Expression of TNF-α immunohistochemical staining sec-
tionsineachgroup.Thepercentageofpositivecellsintenrandomly
selected ﬁelds under high-power microscope (400-fold magniﬁca-
tion) for each sample. The expression of TNF-α in the N group was
weak; it was elevated signiﬁcantly in the M group. EGB treatment
suppressed the expression of TNF-α in a dose-dependent manner
to some degree, but still higher than normal group. The results were
expressed as means
￿ SD.
Westernblotting
The Western blotting results showed that the expressions of
TNF-α,NF-κBp65andIL-6intheMgroupweresigniﬁcantly
increased compared with N group (P<. 01). EGB treatment
decreased the expressions of TNF-α,N F - κBp65 and IL-6 in
a dose-dependent manner to some degree, 5-aminosalicylic
acid reduced the expression, too. EGB in a dose of 200mg/kg
was the most eﬀective in reducing TNF-α,N F - κBp65, and
12 3 456
NF-κBp65
TNF-α
IL-6
β-actin
Figure 4: Western blotting showed levels of TNF-α,N F - κBp65 and
IL-6 in colon tissue of rats. Lane 1: the N group, Lane 2: the M
group, Lane 3: the 5-ASA group, Lane 4: the LD group, Lane 5: the
MD group, and Lane 6: the HD group.
IL-6 levels. (P<. 01, Figures 4 and 5). These experiments
were performed six times with similar results.
RT-PCR
The mRNA levels of TNF-α,N F - κBp65 and IL-6 of the M
group showed a signiﬁcantly high expression compared with
Nc o n t r o l( P<. 01). TNF-α,N F - κBp65, and IL-6 mRNA
expressions were inhibited dose dependently when animals
were treated with EGB and 5-ASA. Maximum inhibition ef-
fect was observed with EGB at a concentration of 200mg/kg.
These results are in accord with Western blotting analysis of
protein expression (P<. 01, Figures 6 and 7). Data is repre-
sentative of colons from at least six rats.
DISCUSSION
The present study demonstrated clearly that EGB in a dose-
dependent manner aﬀected the release of inﬂammatory me-
diators which resulted in a remarkable improvement of in-
ﬂammation injury in TNBS-induced colitis in rats. EGB had6 Mediators of Inﬂammation
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Figure 5: The Western blotting results of TNF-α,N F - κBp65,
and IL-6 were measured by average ratios of TNF-α/β-actin, NF-
κBp65/β-actin and IL-6/β-actin, respectively. The levels of TNF-α,
NF-κBp65, and IL-6 of the M group showed a signiﬁcantly high ex-
pression compared with normal group. EGB treatment decreased
the increase in a dose-dependent manner. The results were ex-
pressed as means
￿ SD.
1 2 34 56 7
NF-κBp65 493bp
357bp TNF-α
557bp IL-6
308bp GAPDH
Figure 6:TNF-α,NF -κBp65,IL-6,andGAPDHmRNAexpressions
incolon tissues.Lane1: 100bpmarker,Lane2: theNgroup, Lane3:
the M group, Lane 4: the 5-ASA group, Lane 5: the LD group, Lane
6: the MD group, and Lane 7: the HD group.
a basic character, antioxidant properties and antiinﬂamma-
tory functions, and these eﬀects most probably contributed
to its therapy of the ulcerative colitis. Compared with the
model group, treatment with EGB for 4 weeks signiﬁcantly
reduced colon macroscopic and histological damage in a
dose-dependent manner.
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Figure 7: The mRNA expressions of TNF-α,N F - κBp65, and
IL-6 were measured by average ratios of TNF-α/GAPDH, NF-
κBp65/GAPDH, and IL-6/GAPDH, respectively. RT-PCR analysis
showed increased TNF-α,N F - κBp65, and IL-6 mRNA levels in
colon tissues of the M group; EGB could reduce the mRNA expres-
sionsdosedependently,whichwereconsistentwiththeWesternblot
analysis. The results were expressed as means
￿ SD.
TNBS-induced colitis was widely adopted to observe the
eﬀects of drugs because of its similarity to human IBD and
the availability of a quantitative scoring system. It was char-
acterized by oxidative stress, mucosal inﬁltration by poly-
morphonuclear cells, at least in part, the activation of TNF-α
and IL-6 and activation of the NF-κB pathway, led to inﬂam-
mation cascade eﬀects and tissue damage [7, 24].
Oxidative stress and its consequent lipid peroxidation
could aggravate free radicals chain reactions, disrupt the in-
tegrity of intestinal mucosa barrier, and activate inﬂamma-
torymediators.IthasbeenshownthatcolonicMDAcontents
increased and colonic SOD Levels decreased both in human
and experimental animal studies [25, 26]. The levels of MDA
were often used as an indication of oxidative damage and as
a marker for free radicals-induced lipid peroxidation. SOD, a
primarydefense,couldreducetheoxidativestressandtheac-
tivation of inﬂammatory mediators. Segui et al [27]r e p o rt e d
that administration of SOD signiﬁcantly reduced lipid per-
oxidation, recruited leukocytes into the inﬂamed intestine
and ameliorated colonic inﬂammatory in UC. Some previ-
ous data have showed that the levels of MDA were decreased
and SOD were increased by antioxidant and antiinﬂamma-
tory agents in UC [28]. EGB acting as free radical scavenger
has been shown to have an SOD-like activity. EGB could
counteract the function of ROS, directly scavenge superoxide
anion, hydroxyl radicals, peroxyl radical species, and nitric
oxide [18, 29]. EGB has been reported to enhance the ac-
tivities of SOD to decrease lipidperoxidation in liver ﬁbrosis
induced by carbon tetrachloride (CCl4) [30]. In our study,
compared with the N group, the Levels of SOD in colonYan-Hong Zhou et al 7
tissue dwindled, while MDA contents improved remarkably
in the M group. Therapy with EGB for 4 weeks resulted in
a marked increase in SOD and decrease in MDA in colon
tissue in a dose-dependent manner. Our results suggested
that EGB successfully inhibited lipid peroxidation induced
by TNBS. EGB provided protective eﬀects in UC probably by
the radical scavenging and antioxidant properties. This may
be an important and underlying mechanism of EGB protec-
tion against UC.
As the most important cytokine in “inﬂammation cas-
cade” of UC, TNF-α stimulated the synthesis of oxygen free
radicals and IL-6, IL-1, NO and other inﬂammatory media-
tors, activated leucocytes, promoted inﬂammatory cells mi-
gration in the intercellular matrix, thus ampliﬁed the in-
ﬂammatory response by activating a cascade of immune cells
[7]. So TNF-α may represent a potential target for down-
regulating the immune and inﬂammatory responses. Oxida-
tive stress was a major factor-activated local inﬂammation
during inﬂammatory process. Intestinal inﬂammation was
considered a consequence of an imbalance between proox-
idant and antioxidant mechanisms [31]. Gossart et al [32]
conﬁrmed that ROS was an early cause of injury and pre-
treatment with free radical scavengers resulted in a decreased
expression of TNF-α in rat’s lung inﬂammation. Consider-
ingourimmunohistochemicalobservation,Westernblotting
analysis,andRT-PCRresults,wefoundthattheexpressionof
TNF-α signiﬁcantly increased in the TNBS model group and
signiﬁcantly reduced in the EGB group in a dose-dependent
manner both at mRNA and protein levels. Our study was
consistent with the results described by Mustafa et al [33],
who found that EGB resulted in a signiﬁcant reduction in
colonic TNF-α levels of colitis rats. They have shown that
EGB could suppress the synthesis, release, and biological ac-
tivity of TNF-α in colitis at least in part by scavenging ROS.
Besides a direct scavenging eﬀect on active oxygen species,
EGB could exert an antiinﬂammatory eﬀect by suppressing
the production of active oxygen and nitrogen species [34].
Our study demonstrated that EGB had marked antiinﬂam-
matory action in addition to its antioxidation properties.
Oxygen free radicals and TNF-α released during inﬂam-
mation could activate NF-κB, a redox-sensitive transcription
factor, and could activate the subsequent inﬂammatory cas-
cade in TNBS-induced colitis in rats, and this process could
be inhibited by EGB. The precise mechanism in which EGB
decreased the levels of NF-κB has not been completely elu-
cidated. Although the interaction between ROS on the NF-
κB signaling pathway has not been completely deﬁned, it has
been suggested that NF-κB could be activated by oxidative
stress and inhibited by antioxidants and radical scavengers
such as vitamin E derivatives, N-acetyl-cysteine, pyrrolidine
dithiocarbamate, and curcumin [35, 36]. All these results in-
dicated that ROS was involved in NF-κB activation process.
Schreck et al [37] indicated that ROS could serve as messen-
gers that directly or indirectly caused the release of IκBf r o m
the p50-p65-IκB complex which had been implicated in the
activation of NF-κB. Wei et al [38] found that EGB could in-
hibit H2O2-induced activation of NF-κB owing to its antiox-
idant properties by directly scavenging H2O2 and elevating
intracellular GSH levels. TNF-α could trigger degradation
of IκB, the inhibitor of NF-κB, then NF-κBe s p e c i a l l yp 6 5
translocated to the nucleus to activate related gene. Chen et
al [39] have showed that EGB could inhibit TNF-α-induced
reactive oxygen species generation and NF-κBa c t i v a t i o ni n
human aortic endothelial cells.
The important discovery of this study was that anti-
inﬂammatory eﬀect of EGB may be linked with down-
r e g u l a t i o ni nN F - κBp65 activity in TNBS induced colitis
in rats. In our study, Western blotting and RT-PCR results
showed that increasing expression of NF-κBp65 in TNBS in-
duced colitis and decreased signiﬁcantly in groups with con-
tinuous 4-week treatment with EGB in a dose-dependent
manner. So we concluded that EGB decreased the activation
of NF-κBp65 by serving as antioxidants. On the other hand
we found that EGB could suppress NF-κBp65 production in
the colitis through inhibited TNF-α-induced NF-κBp65 acti-
vation in colonic mucosa. Then EGB could curb the inﬂam-
matory cascade eﬀects of inﬂammatory mediators to protect
UC.
To further elucidate the mechanism of EGB in UC, we
observed the levels of IL-6, downstream pathway of NF-
κBp65. IL-6 could stimulate neutrophil chemotaxis and re-
late to the presence of necrosis in the colon which led to tis-
sue destruction. Our experiment indicated that the levels of
IL-6 in rat TNBS colitis increased more distinctly than nor-
mal group and declined more obviously after treatment with
EGB in response to TNF-α and NF-κB. Since the promoter
regions of IL-6 had also been shown to contain consensus-
binding motifs for NF-κB. We presumed that the reduced of
IL-6 by EGB might be through modulation of NF-κB.
UC seriously aﬀected the patient’s quality of life in that
no speciﬁc treatment was available and it had a high re-
currence rate. With the development of immunology and
molecular biology, anti-TNF-α antibodies and antisense
oligonucleotides against NF-κB and anti-IL-6R mAb were
eﬀective tools in the treatment of colitis. But their price
was expensive and the safety need to be further identiﬁed
[24, 40, 41]. Thus, EGB, natural antioxidant, was safe and
cheap,anditprovidedaninterestingalternativeapproachfor
the treatment of UC.
Although the antioxidant properties and antiinﬂamma-
tory eﬀects of EGB could exert a beneﬁcial eﬀect in UC, it
was probable that additional mechanisms were also involved.
Cheng et al [42] have found that EGB eﬃciently blocked
several cytokines, including TNF-α production. It was likely
to be mediated through the down-regulation of JNK-AP-1
signaling path in vitro experiment. Future studies from our
group will investigate the upstream pathways of TNF-α and
NF-κBp65 in order to elucidate the active principles and un-
derlying molecular mechanisms.
Inconclusion,thepresentresultsdemonstratedthatEGB
dose dependently exerted a beneﬁcial eﬀect in the TNBS-
induced colitis in rats. As a possible mechanism EGB could
scavenge oxidative-free radicals, down-regulate some of the
inﬂammatory mediators involved in the intestinal immune
and inﬂammatory responses, including TNF-α,N F - κBp65
and IL-6 resulting in the improvement of UC.8 Mediators of Inﬂammation
We suggest that EGB alone or in combination with other
drugsisapromisingagentforthetreatmentofulcerativecol-
itisorisusedasadietarysupplementforpreventionfromthe
recurrence of UC. Further suﬃcient preclinical and clinical
studies should be conducted to prove it.
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